Fresenius Settles With Johnson & Johnson to Market Stelara Alternative
By David Sachs
Pharmaceutical companies Fresenius Kabi and Formycon have reached a settlement with Johnson & Johnson to commercialize a Crohn's Disease drug in Europe and Canada.
Fresenius said Monday that the terms of the settlement for the drug, which mirrors Johnson & Johnson's trademarked Stelara, are confidential. Known as FYB202, the treatment also aids people with plaque psoriasis and ulcerative colitis, and is awaiting approval from regulators.
The settlement follows a similar one with Johnson & Johnson in the U.S. context. Fresenius Kabi and Formycon have had a license agreement in place since last year for marketing the drug after its approval, Fresenius said.
Johnson & Johnson did not immediately respond to a request for comment.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
March 18, 2024 05:51 ET (09:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations